The ApiJect Prefilled Injector is a single-dose, aseptically
filled parenteral that leverages the speed, high output, and quality of the Blow-Fill-Seal (BFS) drug filling process. The Prefilled Injector is made up of
three components: 1) an aseptically filled BFS Container, 2) a stabilizing Connector, and 3) a pen needle-style hub (i.e “Needle Hub”). 

The ApiJect Prefilled Injector is user assembled at the point of
care. All the healthcare worker has to do is push and twist the Needle Hub with the Connector pre-attached on to the top of the BFS Container. The current Prefilled Injector is designed to deliver a 0.25mL - 0.65mL intramuscular dose. 

The ApiJect Prefilled Injector was invented to provide a cost-effective single-dose injectable for global surge capacity. ApiJect has been working with the U.S. Government and the pharmaceutical industry to
expedite development for COVID-19 response.

BARETab® PH is a high functionality homogeneous co-processed compound composed of binder, glidant, disintegrant and lubricant. Co-processing makes the product superior in flowability, compaction, lubricity, disintegration, stability and content uniformity. BARETab® PH performance is superior compared to the individual excipients or their physical mixing. Simplicity in manufacturing process results in higher productivity at lower cost makes BARETab® PH an ideal choice to use as a ready-mix for direct compression formulations.

The BD Evolve™ On-body
Injector is being developed for pharmaceutical companies who seek flexible delivery options, as well as opportunities for improving the patient experience and lowering the cost of care. It supports delivery of biologics with customizable and programmable subcutaneous administration. BD Evolve™ On-body Injector is designed as a flexible system capable of continuous, episodic, or
delayed delivery across a range of volumes, for extended wear and injection durations. It is meant to be programmable, with connected capabilities, and to enable subcutaneous administration of up to 3 mL of medication with up to 3 days of wear, allowing for medication delivery in a non-clinical setting.

Needle length and, most importantly, needle inner diameter are key parameters influencing injection force for a given injection time and solution viscosity. Reducing the injection force required to deliver solutions by manual
injection is a parameter influencing patient preference, especially when high
viscosities are injected. BD Medical - Pharmaceutical Systems is launching BD Neopak™ XtraFlow™ – a prefillable glass-based syringe solution featuring an 8 mm needle with thinner wall cannula technology. Enabling the transition from the 12.7 mm needle length towards shorter 8 mm needles, in combination with thinner wall needle
technology to reduce pressure drop and enhance flow, can provide improved PFS solutions for subcutaneous drug delivery both for end-users in chronic care settings and for pharmaceutical companies.

Bifivir® is a synbiotic food supplement for an effective immune system, based on 5
different probiotic strains and 3g of prebiotic fiber fructooligosaccharides (B.
animalis subsp. lactis BS01, L. plantarum LP01 and LP02, L.
rhamnosus LR04 and LR05 and FOS). Bifivir® has been tested in several clinical trials involving in total nearly 900 adults over three different winter periods, and its daily intake led to a significant reduction in
prevalence, severity and duration of respiratory tract infections and influenza-like illnesses, including flu, by about half. The strains are also
backed by a preclinical dossier on their mechanisms of action which include the reinforcement of the gut membrane to protect from leaky gut, the antagonism towards pathogens, including respiratory infectious agents like K. pneumoniae, and the activation of an immunosurveillance response while keeping inflammation
in check.

Bifizen® is a probiotic combination of 4 strains selected for complementary mechanisms of action to benefit the gut-brain axis: L. fermentum LF16, L. rhamnosus
LR06, B. longum 04 and L. plantarum LP01. Bifizen supplementation for 6 weeks in healthy students showed significant benefits in depressive mood, anger, fatigue and quality of sleep, benefits prolonged in time even 3 weeks after the washout period. Bifizen is now declined as a range of 5 food supplements for mental well-being for the whole family: Bifizen Stress, Bifizen
Focus, Bifizen Night, Bifizen Age Well and Bifizen Kids, which are based on tested and validated combinations of the probiotic strains with well-established natural ingredients like science-based botanical extracts and vitamins allowing claims. With these 24 months shelf-stable products,
Probiotical is able to answer the rising demand for holistic natural solutions for mental wellbeing and performance.

Ackley’s highly versatile Cantilever Ramp Laser is now available with precision UV Laser technology to mark indelible logos onto tablets and capsules of all shapes and sizes for identification, counterfeit protection, and brand recognition. This non-contact, ultraviolet laser writing system marks and inspects up to 150,000 pharmaceutical products per hour, delivering consistent, high quality output. The Cantilever Ramp Laser
features a continuous motion, multi-lane carrier bar system that exposes the top surface of the product for laser processing and vision inspection. The Cantilever is a Class 1 Laser Product that is user friendly, affordable and requires only compressed air and power for operation.

Non-adherence not only jeopardizes the success of treatment, but also causes immense costs for the healthcare systems. However, if the patient receives immediate feedback on the correct use of their medicine, this can significantly increase treatment adherence.

This is where Connect-e-Cap comes in, the intelligent
packaging solution by Röchling Medical. The electronics and sensor technology integrated into the cap combined with NFC connectivity support patients with taking their medicine correctly.  

A wide range of features allows for identifying complex patterns of patient behaviour and multi-cause non-adherence. Due to Connect-e-Cap‘s modular design, feature combinations can be precisely tailored to the intended use.

Daptomycin is an antibacterial (cyclic lipopeptide natural product) that is active against Gram positive bacteria and isindicated for the treatment of the following infections:Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI). - Adultpatients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It is recommended that thedecision to use daptomycin should take into account the antibacterial susceptibility of the organism and should bebased on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use inbacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should beassociated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certaintypes of anaerobic bacteria are suspected, Daptomycin should be coadministered with appropriate antibacterialagent(s).

Lacosamide is a functionalised amino acid which belongs to the group of antiepileptics. In vitro electrophysiological
studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes. Lacosamide is used as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children
from 4 years of age with epilepsy.

Linezolid is a synthetic antibacterial agent that belongs to oxazolidinones. It has in vitro activity against aerobic Gram positive bacteria and anaerobic micro-organisms. Linezolid selectively inhibits bacterial protein synthesis via a unique
mechanism of action. Linezolid is used for Nosocomial pneumonia, Community acquired pneumonia and complicated skin and soft tissue infections.

Mannogem® XL Opal helps pharmaceutical formulators overcome many of the common challenges of working with mannitol. At 160 µm, it is ideal for use as a base for ordered mixing with micronized APIs and low-dose
formulations, providing superior binding properties and tabletability over standard spray-dried mannitols and other excipients. 

Opal enables rapid and effective formulation of convenient, patient-friendly dosage forms, such as ODTs, chewable tablets and soft-chews. Properties such as quick disintegration, excellent mouthfeel with pleasant
organoleptics are essential for drug adherence and to treat vulnerable populations and children. 

Simplified formulations and consistency are made easy by
using less excipients and enhancing content uniformity. This leads to faster development and lower costs. Contact us to discuss or request a sample!